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INTRODUCTION
Since the Breast Imaging Reporting and Data System 
(BI-RADS) was first developed to provide a lexicon of 
breast imaging findings, assessment, and management 
recommendations to facilitate communication between 
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radiologists and referring physicians, it has been 
revised several times. In the 5th edition, the lexicon 
for mammographic calcification morphology has been 
consolidated into two categories, typically benign and 
suspicious, after combining the “intermediate concern” 
and “higher probability” categories of the 4th edition (1). 
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For BI-RADS final assessment, the 5th edition suggests 
the use of category 2 (typically benign), category 3 
(solitary grouped punctate), category 4B (amorphous, 
coarse heterogeneous, fine pleomorphic), and category 
4C (fine linear or linear branching) for calcifications, but 
categories 4A and 5 are not specified despite common use 
in daily practice (2). Previous studies investigated the 
categorization of calcifications by combining morphology 
and distribution but focused on the integration of category 
4A into the category 4 subdivision and did not investigate 
the use of categories 3 or 5 (2, 3). In addition, punctate 
calcification, although described in the section on round 
calcification as typically benign, may warrant a probably 
benign assessment (category 3) if found as an isolated 
group or imaging-guided biopsy if appearing as linear or 
segmental, but no data are present (4). Therefore, further 
evaluation is needed that embraces the use of categories 
3 and 5 with category 4 subdivision and punctate 
calcification, and a nomogram such as a scoring system 
could be developed to stratify malignancy risk according to 
the BI-RADS lexicon. 
The purpose of the present study was to develop a scoring 
system stratifying the malignancy risk of mammographic 
microcalcification in the 5th edition of BI-RADS. 
MATERIALS AND METHODS
This retrospective study was approved by the Institutional 
Review Boards of Gangnam Severance Hospital and Chonbuk 
National University Hospital, and the requirement for 
written informed consent from participants was waived. 
Between August 2015 and July 2017, 208 consecutive 
surgical excisions were performed after needle localization 
under mammographic guidance for microcalcifications 
assigned as BI-RADS category 4 or 5 at Gangnam Severance 
Hospital. Fourteen cases did not have preoperative 
mammograms and were therefore excluded. Thus, a total 
of 194 microcalcifications in 183 women (mean age, 49.8 
± 8.5 years; range, 34–75 years) were included and used 
to develop a scoring system for stratifying malignancy risk 
in this study. The validation set for testing the developed 
scoring system consisted of 100 surgically excised 
microcalcifications in 100 women (mean age, 54.5 ± 9.5 
years; range, 29–77 years) at Chonbuk National University 
Hospital from August 2013 to August 2018 under the same 
inclusion criteria. 
Mammography Examination and Interpretation
Standard mediolateral oblique and craniocaudal 
mammograms or magnified views of microcalcifications 
were obtained with a full-field digital mammography unit 
(Lorad Selenia, Hologic, Marlborough, MA, USA). All images 
were reviewed at a dedicated review workstation (Lorad 
Selenia Softcopy Workstation, Hologic) by two breast 
specialists with 6 and 17 years, respectively, of experience 
in interpreting digital mammography. Radiologists were 
asked to assign the single most appropriate descriptor 
and a BI-RADS final assessment category of 3, 4A, 4B, 4C, 
or 5 for each lesion according to the 5th edition of BI-
RADS, as categories 0, 1, 2, and 6 were not included (4). In 
addition, BI-RADS categories were reassigned according to 
the recommendations of the 5th edition of BI-RADS and a 
previous study (3, 4). 
For the validation dataset, mammograms were obtained 
with two digital mammography units (Senographe DS, GE 
Healthcare, Chicago, IL, USA; Siemens Mammomat Novation 
DR, Siemens, Munich, Germany) and all images were 
reviewed at a dedicated review workstation (SenoAdvantage, 
GE Healthcare) by two breast specialists with 5 and 9 
years of experience, respectively, in interpreting digital 
mammography. 
Statistical Analysis
Positive predictive value (PPV) of BI-RADS descriptors 
and BI-RADS categories were analyzed using generalized 
estimating equations with post-hoc analysis. The diagnostic 
performances of BI-RADS descriptors, BI-RADS categories, 
and the scoring system were evaluated and compared 
between our reviewers’ assessments and the 5th edition of 
BI-RADS or a prior study using the area under the receiver 
operating characteristic curve (AUROC) (3-5). A scoring 
system stratifying the malignancy risk of microcalcifications 
was developed based on multivariate logistic regression 
analysis for the BI-RADS descriptors. The scores of benign 
and malignant lesions as well as visually assessed BI-RADS 
categories were compared using an independent t test or 
ANOVA. The discriminatory ability of our scoring system was 
assessed for the risk of malignancy by obtaining the AUROC. 
The cutoff value for each BI-RADS category was determined 
based on the PPV of the scoring system according to 
the 5th edition of BI-RADS (4). Our scoring system was 
validated using an external dataset of 100 women.
Statistical analyses were performed with a software 





After surgical excision, 69 microcalcifications were 
diagnosed as malignant (35.6% of 194; 50 ductal 
carcinomas in situ, 18 invasive ductal carcinomas, and 1 
invasive lobular carcinoma) and 125 microcalcifications 
were diagnosed as benign, including 7 cases of atypical 
ductal hyperplasia, 5 cases of flat epithelial atypia, and 
2 cases of atypical papilloma. For the validation dataset 
of 100 microcalcifications, 35 (35%) were diagnosed as 
malignant (29 ductal carcinomas in situ and 6 invasive 
ductal carcinomas) and 65 were diagnosed as benign, 
including 2 cases of atypical ductal hyperplasia and 1 case 
of flat epithelial atypia. 
Assessment of Microcalcification according to BI-RADS 
Descriptors
The PPVs of BI-RADS descriptors and categories for 
microcalcifications were significantly different among 
variables (Table 1). A trend in increasing PPV was observed 
from amorphous (13.0%) or coarse heterogeneous (11.1%) 
to fine pleomorphic (68.5%) and fine linear or linear 
branching (85.7%) morphology, and from regional (10.0%) 
or grouped (26.1%) to linear (67.5%) and segmental 
(75.5%) distribution. No cancer was observed in cases of 
punctate or diffuse calcification. Even after examining 
Table 1. PPV of Morphology, Distribution, and Final Assessment Category of Mammographic Microcalcifications according to BI-
RADS 5th Edition
Variables
Our Dataset Validation Dataset
PPV (%) P† AUROC (95% CI) PPV (%) P†
Morphology 0.826 (0.783–0.869)
Punctate 0 (0/15) > 0.99 0 (0/21) > 0.99
Amorphous 13.0 (19/146) < 0.001 6.3 (4/63) 0.039
Coarse heterogeneous 11.1 (8/72) 0.003 13.3 (4/30) 0.032
Fine pleomorphic 68.5 (87/127) < 0.001 63.6 (35/55) < 0.001
Fine linear or linear branching 85.7 (24/28) < 0.001 87.1 (27/31) < 0.001
Distribution 0.716 (0.670–0.761)
Diffuse 0 (0/4) > 0.99 0 (0/1) > 0.99
Regional 10.0 (3/30) 0.068 5.6 (1/18) 0.304
Grouped 26.1 (68/261) < 0.001 29.5 (38/129) < 0.001
Linear 67.5 (27/40) < 0.001 63.0 (17/27) < 0.001
Segmental 75.5 (40/53) < 0.001 56.0 (14/25) < 0.001
Reviewer assessment 0.875 (0.839–0.912)
Category 3 0 (0/18) > 0.99 0 (0/31) > 0.99
Category 4A 9.1 (14/154) < 0.001 6.9 (4/58) 0.038
Category 4B 24.4 (22/90) < 0.001 35.7 (20/56) < 0.001
Category 4C 70.8 (51/72) < 0.001 77.1 (27/35) < 0.001
Category 5 94.4 (51/54) < 0.0001 95.0 (19/20) < 0.001
Assessment based on BI-RADS (4) 0.680* (0.635–0.724)
Category 3 0 (0/19) > 0.99 - -
Category 4A N/A (0/0) N/A - -
Category 4B 28.0 (79/282) < 0.001 - -
Category 4C 67.8 (59/87) < 0.001 - -
Category 5 N/A (0/0) N/A - -
Assessment based on Kim et al. (3) 0.785* (0.741–0.828)
Category 3 0 (0/15) > 0.99 - -
Category 4A 13.3 (17/128) < 0.001 - -
Category 4B 34.1 (57/167) < 0.001 - -
Category 4C 82.1 (64/78) < 0.001 - -
Category 5 N/A (0/0) N/A - -
*p < 0.0001, in comparison with reviewer assessment, †p values, in comparison of PPV with other variables’ PPVs. AUROC = area under 
receiver operating characteristic curve, BI-RADS = Breast Imaging Reporting and Data System, CI = confidence interval, N/A = not 
available, PPV = positive predictive value
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pairwise comparisons, the PPV differed significantly 
among all descriptors and categories (p < 0.03), except for 
between amorphous and coarse heterogeneous morphology 
(p = 0.68), between diffuse and regional distribution (p = 
0.07), and between linear and segmental distribution (p 
= 0.40). The AUROC of our study (0.875) was significantly 
higher than those for the recommendations in the 5th 
edition of BI-RADS (0.680) and in the previous study (0.785) 
(p < 0.0001) (Table 1). 
Scoring System for Microcalcification
The scoring system was derived from the multivariate 
regression model based on the sum of β coefficients for BI-
RADS descriptors as follows (Table 2): score = (1.4671 x 
amorphous) + (1.3076 x coarse heterogeneous) + (3.8426 
x fine pleomorphic) + (4.3709 x fine linear or linear 
branching) + (-0.7505 x regional) + (0.2299 x grouped) 
+ (1.2686 x linear) + (1.6154 x segmental). Mean scores 
differed significantly between benign (mean, 2.01 ± 1.22) 
and malignant microcalcifications (mean, 4.27 ± 1.36) 
(p < 0.001) and among BI-RADS categories with post-
hoc analysis: category 3 (mean, 0.47 ± 0.48), category 4A 
(mean, 1.66 ± 0.60), category 4B (mean, 2.59 ± 1.25), 
category 4C (mean, 4.31 ± 0.97), and category 5 (mean, 
5.28 ± 0.61) (p < 0.001). The discriminating ability of the 
scoring system was an AUROC of 0.874 (95% confidence 
interval [CI], 0.840–0.909) (Fig. 1A). The PPVs of combined 
BI-RADS morphologies and distributions according to our 
scoring system are summarized in Table 3. The score cut-
off values and ranges for each category were determined by 
PPVs in the scoring system as follows: < 1.5 category 3 (PPV, 
0%); 1.5 ≤ category 4A < 1.6 (PPV, 6.8%); 1.6 ≤ category 
4B < 4.0 (PPV, 19.0%); 4.0 ≤ category 4C < 5.5 (PPV, 
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68.2%); 5.5 ≤ category 5 (PPV, 100%) (Table 4). 
In the validation dataset, the AUROC was 0.893 (95% CI, 
0.851–0.935) for the final assessment category after visual 
assessment according to the 5th edition of BI-RADS by two 
reviewers. After applying the scoring system, mean scores 
differed significantly between benign (mean, 1.95 ± 1.38) 
and malignant microcalcifications (mean, 4.51 ± 1.08) (p 
< 0.001) and among visually assigned categories: category 
3 (mean, 0.65 ± 0.68), category 4A (mean, 1.82 ± 0.99), 
category 4B (mean, 3.38 ± 1.24), category 4C (mean, 4.32 
± 1.21), and category 5 (mean, 5.16 ± 0.78) (p < 0.001). 
The discriminating ability of the scoring system was an 
AUROC value of 0.905 (95% CI, 0.864–0.946) (Fig. 1B). The 
PPV of each BI-RADS category determined by the scoring 
system was 0%, 8.3%, 11.9%, 68.3%, and 94.7% of PPVs 
for categories 3, 4A, 4B, 4C, and 5, respectively (Table 4). 
DISCUSSION
Recently, the cost-benefit analysis of screening 
mammography has been closely examined. False-positive 
results and unnecessary recalls or biopsies are considerable 
disadvantages of screening. The appropriate application 
of BI-RADS category 4 and its subdivision, which account 
for the majority of tissue diagnosis recommendations, 
is a crucial aspect of addressing these concerns (6, 7). 
Unfortunately, category 4 subdivisions are infrequently 
utilized (33%) and used even less for calcifications than 
for architectural distortion or asymmetry (7). Meanwhile, 
recalls for calcifications were much more likely to lead to 
biopsy compared to other findings (8). Even after biopsy, 
the recommended management should vary according 
to the likelihood of malignancy for calcifications. For 
example, benign pathology results for category 4A lesions 
may be concordant and surveillance can be recommended, 
but for category 4B or 4C lesions, clinicians should 
deliberate over concordant benign pathology results (3). 
However, BI-RADS does not provide clear guidance nor 
specify category 4A or 5 for mammographic calcification. 
Thus, radiologists might find it difficult to assign BI-
RADS categories, including the category 4 subdivision 
for calcification, which could lead to a higher biopsy 
rate after recall. In the present study, a scoring system 
based on the BI-RADS lexicon was developed to suggest a 
guideline that more appropriately utilizes categories 3 to 
5 with category 4 subdivision by combining morphology 
and distribution of calcification. The 5th edition of BI-
RADS places three morphology descriptors of ‘suspicious’ 
calcifications (amorphous, coarse heterogeneous, and fine 
pleomorphic) in category 4B, with their PPV ranging from 
13% to 26% (average, 20%) (4). Prior studies revealed 
the lowest PPV of amorphous calcification to range from 
7.2% to 10.5%, even within the range of category 4A (2, 
3, 9). To stratify its likelihood of malignancy and reduce 
unnecessary biopsies, ‘grouped’ amorphous calcification was 
investigated and lowered all PPVs, which ranged from 2.8% 
to 7.6%, corresponding to category 3 or 4A (2, 3, 6, 9). 
In our study, however, coarse heterogeneous morphology 
had a lower PPV (11.1%) than amorphous morphology 
(13.0%) (Table 1), and ‘grouped’ coarse heterogeneous 
calcification had much lower PPV (7%) than ‘grouped’ 
amorphous calcification (16%). A prior study also reported 
a lowest PPV for coarse heterogeneous calcification (3%) 
Table 3. PPVs of Combined BI-RADS Morphology and Distribution according to Our Scoring System
BI-RADS 
Lexicons
Diffuse Regional Grouped Linear Segmental
PPV (%) Score PPV (%) Score PPV (%) Score PPV (%) Score PPV (%) Score
Punctate N/A 0 N/A -0.7505 0 (0/15) 0.2299 N/A 1.2686 N/A 1.6154
Amorphous 0 (0/4) 1.4671 0 (0/17) 0.7166 15.9 (17/107) 1.6970 9.1 (1/11) 2.7357 14.3 (1/7) 3.0825
Coarse 
  heterogeneous
N/A 1.3076 0 (0/7) 0.5571 6.8 (4/59) 1.5375 0 (0/1) 2.5762 80.0 (4/5) 2.9230
Fine pleomorphic N/A 3.8426 50.0 (3/6) 3.0921 59.7 (43/72) 4.0725 88.2 (15/17) 5.1112 81.3 (26/32) 5.4580
Fine linear or 
  linear branching
N/A 4.3709 N/A 3.6204 50.0 (4/8) 4.6008 100 (11/11) 5.6395 100 (9/9) 5.9863
Table 4. Score Ranges for BI-RADS Final Assessment 





Our Dataset Validation Dataset
Category 3 < 1.5 0 (0/43) 0 (0/35)
Category 4A 1.5 ≤ x < 1.6 6.8 (4/59) 8.3 (2/24)
Category 4B 1.6 ≤ x < 4.0 19.0 (26/137) 11.9 (7/59)
Category 4C 4.0 ≤ x < 5.5 68.2 (88/129) 68.3 (43/63)
Category 5 5.5 ≤ 100 (20/20) 94.7 (18/19)
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(10). Coarse heterogeneous calcification first appeared in 
the 4th edition of BI-RADS and its 13% average PPV in 
the 5th edition was based on the results of two studies 
with a total sample size of 24, lower than the average of 
21% for amorphous calcification (11, 12). According to our 
scoring system, coarse heterogeneous calcification can be 
stratified into category 4A when combined with a grouped 
distribution for a score of 1.5375 and into category 3 
when combined with a diffuse or regional distribution 
with a score < 1.5. Amorphous calcifications can be also 
stratified into category 3 when combined with a diffuse or 
regional distribution with a score < 1.5, but into category 
4B when combined with a grouped distribution. All cases of 
category 3 calcification based on the scoring system were 
benign in both datasets. Beyond the guidelines suggested 
by prior studies, our scoring system provides stratified 
recommendations from category 3 through category 5 
assessment including category 4 subdivisions by combining 
every morphology or distribution descriptor (2, 3, 13). 
Fine linear or linear branching calcifications with linear 
or segmental distributions can be included in category 
5 in our scoring system with a score ≥ 5.5 and a PPV of 
100% and 95% in our and validation dataset, respectively 
(Tables 3, 4). In two previous studies, amorphous, coarse 
heterogeneous, and fine pleomorphic calcifications with a 
diffuse distribution were all benign, but diffuse distribution 
was not included in the recommendations (2, 3). In a prior 
study, all fine linear or linear branching calcifications were 
malignant, regardless of distribution, but were placed in 
category 4C instead of category 5 (3). In addition, diffuse 
or regional distribution for fine pleomorphic or fine linear 
or linear branching calcifications could not be assigned to 
any BI-RADS category in a prior study because of a lack of 
available data (2). Another prior study provided a BI-RADS 
category only after grouping the morphology descriptor into 
typically benign, indifferent, or typically malignant, and not 
for an individual morphology descriptor (13). 
Punctate calcification is a subset of round calcification 
that is < 0.5 mm in the ‘typically benign’ section. However, 
isolated groups of punctate calcifications may warrant 
category 3 classification and mammographic surveillance 
if no prior examinations are available for comparison, or 
image-guided biopsy if the group is linear or segmental 
(4). Nonetheless, punctate calcification was not dealt with 
in prior studies of the 5th edition of BI-RADS (2, 3). In 
our study, reviewers were asked to designate lesions as 
category 3 or higher for calcifications and 15 lesions were 
designated as punctate. According to our scoring system, 
diffuse, regional, grouped, or linear punctate calcifications 
are supposed to be classified into category 3 and segmental 
punctate calcifications are supposed to be placed in 
category 4B. Because a relatively small number of punctate 
calcifications were analyzed and all were benign in our 
study, further investigation is required for the assessment 
of punctate calcification.
With regard to the diagnostic performance of our scoring 
system for mammographic calcification, good performance 
was observed with an AUROC of 0.874 for our dataset 
and 0.905 for the validation dataset. Compared with the 
5th edition of BI-RADS (AUROC, 0.680) and a prior study 
(AUROC, 0.785), our scoring system for categories 3 
through 5 including category 4 subdivision showed higher 
performance (3, 4). This stands to reason because the 5th 
edition of BI-RADS allows only category 4B and 4C and 
the guideline of the prior study provided only category 4 
subdivisions, and not category 5. Considering that all cases 
underwent surgery in our study, unnecessary surgery could 
have been avoided in cases designated category 3 using 
this scoring system: 11.1% (43 of 388) of cases in our 
dataset and 17.5% (35 of 200) of cases in the validation 
dataset. 
There are some limitations to our study. First, this was 
a retrospective study with a relatively small number of 
enrolled patients and there might have been a selection 
bias because only excised lesions were included. Further 
large-scale investigation is needed to include more 
amorphous, coarse heterogeneous, diffuse, or regional 
calcification cases. Second, we reviewed mammographic 
findings of calcification at the time of examination, but 
comparison with prior examinations was not performed 
to establish new development, increases, or suspicious 
changes, which would be considered beyond BI-RADS 
descriptors in practice (14). Third, patient characteristics 
were not used to stratify the likelihood of malignancy. A 
prior study reported that grouped amorphous calcifications 
in women younger than 50 years without a history of breast 
or ovarian cancer showed a low malignancy rate (9). Further 
studies will be needed to incorporate patient characteristics 
and chronological information into this scoring system. 
Lastly, interobserver variability was not evaluated for BI-
RADS descriptors and final assessment categories for 
mammographic microcalcifications. 
In conclusion, a scoring system based on morphology 




could be used to stratify malignancy risk and to assign 
final BI-RADS assessment categories for mammographic 
microcalcifications.
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